Double-Masked Controlled Trial of H-1337 as a Treatment for Glaucoma and Ocular Hypertension
H-1337 in doses of 0.6% b.i.d., 1.0% q.d., and 1.0% b.i.d. had ocular hypotensive efficacy in the range of timolol, although not within the strict Phase 3 non-inferiority margins, which would have required a larger sample size.
Authors
- Robert D. Williams (ORCID: https://orcid.org/0000-0002-5719-4921)
- Lee Shettle
- Jay Mulaney
- Gary D. Novack (ORCID: https://orcid.org/0000-0002-9699-8543)
- Jennifer Beck (ORCID: https://orcid.org/0000-0003-0139-9271)
- Jeanette A. Stewart
Institutions
- Eye Institute of West Florida (US)
- Central Florida Eye Institute (US)
- Research Network (United States) (US)
- University of California, Davis (US)
Publication Details
- Journal
- Journal of Ocular Pharmacology and Therapeutics
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1177/10807683251393984
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00